SLC5A2 and type 1 diabetes mellitus: The increased frequency observed in T1DM can be explained by the renal and pancreatic effects of SGLT2-inhibitors that are emphasized in patients in add-on combination therapy with insulin, since to minimize the risk of hypoglycemia it is necessary to decrease the insulin dose.